Clinical experience with transdermal and orally administered opioids in palliative care patients - A retrospective study

Japanese Journal of Clinical Oncology

Volumn 37, Issue 4, 2007, Pages 302-309

  Clemens, Katri Elina ^a,b   Klaschik, Eberhard ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b Malteser Hospital Bonn/Rhein Sieg   (Germany)

Author keywords

Cancer pain; Equianalgesic dose; Opioid switching; Opioid related side effects; Palliative care

Indexed keywords

AMITRIPTYLINE; DIPYRONE; FENTANYL; FLUPIRTINE; GABAPENTIN; HYDROMORPHONE; IBUPROFEN; LAXATIVE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; ANALYSIS OF VARIANCE; ARTICLE; CACHEXIA; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; DEMOGRAPHY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPERIENCE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANK SUM TEST; RATING SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; SWEATING; SYMPTOM;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; HYDROMORPHONE; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PATIENT SATISFACTION; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 34447619740     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym017     Document Type: Article

References (43)

1. Zorn M, Rowland JH, Varricchio CG. Symptom management in cancer: Pain, depression, and fatigue. National Library of Medicine, Bethesda, MD 2002, 1-26; at http://www.nlm.nih.gov/pubs/cbm/cancersymptoms.html
2. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-6.
3. Foley KM. The treatment of cancer pain. N Engl J Med 1985;313:84-95.
4. Report of a WHO Expert Committee. Cancer Pain Relief. Geneva, Switzerland, World Health Organization 1996.
5. Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer 2001;84:587-93.
6. Lindena G, Arnau H, Liefhold J. Hydromorphon - pharmakologische Eigenschaften und therapeutische Wirksamkeit. Schmerz 1998;12:195-204.
7. Report of the WHO Expert Committee. Cancer Pain and Palliative Care. World Health Organ Techn Rep Ser 1990;804:24.
8. Babul N, Hain R. Hydromorphone and metabolite pharmacokinetics in children. J Pain Symptom Manage 1995;10:335-7.
9. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and quidelines. J Clin Oncol 1984;2:187-93.
10. World Health Organization. Cancer Pain Relief. Geneva, Switzerland, World Health Organization 1986.
11. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained release oral morphine in cancer pain: Preference, efficacy and quality of life. J Pain Symptom Manage 1997; 13:254-61.
12. Gourlay GK. Treatment of cancer pain with transdermal fentanyl. Lancet Oncol 2001;2:165-72.
13. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998;16:1588-93.
14. Jeal W, Benfield P. Transdermal fentanyl. A review of its efficacy in pain control. Drugs 1997;53:109-38.
15. Foley KM, Houde RW. Methadone in cancer pain management: Individualize dose and titrate to effect. J Clin Oncol 1998;16:3213-5.
16. Yeo W, Lam KK, Chan AT, Leung TW, Nip SY, Johnson PJ. Transdermal fentanyl for severe cancer-related pain. Palliat Med 1997;11:233-9.
17. Benitez-Rosario MA, Feria M, Salinas-Martin A, Martinez-Castillo L, Martin-Ortega JJ. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer 2004;101:2866-73.
18. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain. Drugs 2001;61:2289-307.
19. Eisenberg E, McNicol ED, Carr DB. Efficacy of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trias. JAMA 2005;293:3043-52.
20. Przewlocki R, Przewlocka B. Opioids in neuropathic pain. Curr Pharm Des 2005;11:3013-25.
21. Enting RH, Oldenmenger WH, van der Rijt CC, Wilms EB, Elfrink EJ, Elswijk I, et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral oipioids. Cancer 2002;94:3049-56.
22. Santiago-Palma J, Khojanova N, Kornic C, Fischberg DJ, Primavera LH, Payne R, et al. Intravenous methadone in the management of chronic cancer pain: Safe and effective starting doses when substituting methadone for fentanyl. Cancer 2001;92:1919-25.
23. DeStoutz ND, Bruera E, Suarez-Almanzor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-84.
24. Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-Almazor ME, et al. Occurrence, causes and outcome of delirium in patients with advanced cancer: A prospective study. Arch Intern Med 2000;160:786-94.
25. Berger A, Smith M, Lidsky L, Seifeldin R, Oster G. Opioid use and health care charges at the end of life in patients with metastatic cancer. Manag Care Interface 2004;17:28-34.
26. Welsh J, Reid A, Graham J, Curto J, MacLeod K, O'Neill C. Physicians' knowledge of transdermal fentanyl. Palliat Med 2005;19:9-16.
27. Ellershaw JE, Kinder C, Aldridge J, Allison M, Smith JC. Care of dying: is pain control compromised or enhanced continuation of the fentayl transdermal patch in the dying phase? J Pain Symptom Manage 2002;24:398-403.
28. Allan L, Hays H, Jensen NH, Le Polain de Waroux B, Bolt M, Donald R, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001;12(322,7295):1154.
29. Cherny N. New strategies in opioid therapy for cancer pain. J Oncol Manag 2000;9:8-15.
30. Radbruch L, Elsner F. Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany. Keio J Med 2004;53:23-9.
31. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: Focus on transdermal fentanyl. Clin Pharmacokinet 2000;38:59-89.
32. Janssen Pharmaceutica Products. Durogesic (fentanyl transdermal system) [drug summary information]. Titusville, NJ: Janssen Pharmacutica Products, L.P. Available from URL: http://www.janssen.com/active/janus/ en_US/asset/jan/durogesic.pdf (accessed August 2005).
33. Lawlor P, Turner K, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: A retrospective study. Pain 1997;7:79-85.
34. Pasero C, McCaffery M. Hydromorphone. A first-line analgesic without clinically relevant metabolites. Am J Nurs 2001;101:22-3.
35. Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing conversion dilemmas. J Pain Symptom Manage 2001;21:397-406.
36. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. A critical review and proposals for long term dosing. J Pain Symptom Manage 2001;22:672-87.
37. Mercandante S, Ferrera P, Villari P, Casaccio A. Rapid switching between transdermal fentanyl and metadone in cancer patients. J Clin Oncol 2005;23:5229-34.
38. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004;(3):CD004847.
39. Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration and opiate rotation. J Pain Symptom Manage 1995;10:287-91.
40. MacDonald N, Der L, Allan S, et al. Opioid hyper excitability - the application of alternate opioid therapy. Pain 1993;53:353-5.
41. Babul N, Darke AC. Putative role of hydromorphone metabolites in myoclonus. Pain 1992;51:260-1.
42. Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC. Steady state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled release hydromorphone. J Clin Pharmacol 1995;35:37.
43. Stamer UM, Bayere B, Stuber F. Genetics and variability in opioid response. Eur J Pain 2005;9:101-4.